Allie Gemmill is the Lead News Editor at Collider. Previous bylines can be found at Bustle, Teen Vogue, Inverse, ScreenRant, SheKnows, VICE, and Atom Tickets. It's the best of times and the worst of ...

Earning $870,000 on 2,542 screens, "The Goldfinch" is unlikely to cross $3 million on its opening weekend. The writing was on the walls when even the stars of the sprawling epic publicly said that ...

Goldfinch Bio is a biotechnology company that develops precision therapies for kidney disease. The company's platform uses genomic and proteomic data to identify and develop targeted therapies for ...

Matt Goldberg has been an editor with Collider since 2007. As the site's Chief Film Critic, he has authored hundreds of reviews and covered major film festivals including the Toronto International ...

From Warner Bros. Pictures and Amazon Studios, “The Goldfinch” is the film adaptation of Donna Tartt’s globally acclaimed best-selling novel, which won the 2014 Pulitzer Prize for Fiction and the ...

Goldfinch Bio, a 2020 Fierce Biotech Fierce 15 winner, is shutting down. CEO Tony Johnson and Chief Financial and Operating Officer Kyle Kuvalanka told Fierce Biotech that the company is closing up ...